Objective To update evidence‐based medicine recommendations for treating nonmotor
symptoms in Parkinson's disease (PD). Background The International Parkinson and Movement …

Objective The Parkinson's Progression Markers Initiative ( PPMI ) is an observational,
international study designed to establish biomarker‐defined cohorts and identify clinical, imaging, …

Background: In 2015, the International Parkinson and Movement Disorder Society
published clinical diagnostic criteria for Parkinson's disease. These criteria aimed to codify/reproduce …

Background and purpose To assess neurological manifestations and health‐related quality
of life (QoL) 3 months after COVID‐19. Methods In this prospective, multicenter, …

The differential diagnosis of parkinsonian syndromes is considered one of the most challenging
in neurology and error rates in the clinical diagnosis can be high even at specialized …

Isolated REM sleep behaviour disorder (RBD) is an early-stage α-synucleinopathy in most,
if not all, affected subjects. Detection of pathological α-synuclein in peripheral tissues of …

Background and purpose Neurological sequelae from coronavirus disease 2019 (COVID‐19)
may persist after recovery from acute infection. Here, the aim was to describe the natural …

Objective The objective of this study was to assess the efficacy and safety of nabilone, a
synthetic tetrahydrocannabinol analogue, as a treatment for non‐motor symptoms (NMS) in …

Background: In 2015, the International Parkinson and Movement Disorder Society published
clinical diagnostic criteria for Parkinson's disease (PD). Although recent validation studies …

Background: Sarcopenia and frailty are found in up to one-third of the general elderly
population. Both are associated with major adverse health outcomes such as nursing home …